ArticleAnnals of clinical and translational neurology2024

Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.

Ilya Kister et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.